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Side Effects of Drugs
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Summary and conclusions
Review of the various drugs in current clinical use
showed that over 50 of them may cause a purely sensory
or mixed sensorimotor neuropathy. These include
antimicrobials, such as isoniazid, ethambutol, ethio-
namide, nitrofurantoin, and metronidazole; anti-
neoplastic agents, particularly vinca alkaloids; cardio-
vascular drugs, such as perhexiline and hydrallazine;
hypnotics and psychotropics, notably methaqualone;
antirheumatics, such as gold, indomethacin, and
chloroquine; anticonvulsants, particularly phenytoin;
and other drugs, including disulfiram, calcium car-
bimide, and dapsone.
Patients receiving drug treatment who complain of
paraesthesiae, pain, muscle cramps, or other abnormal
sensations and those without symptoms who are receiving
drugs that are known or suspected to be neurotoxic
should undergo neurological examination and studies of
motor and sensory nerve conduction. This will allow the
incidence of drug-induced peripheral neuropathy to be
determined more precisely.
Introduction
Various drugs may cause peripheral nerve damage when used
therapeutically.1 2Some, such as thalidomide and clioquinol,
have been withdrawn from clinical use, while others are still
freely prescribed. In this review we deal only with the second
group of drugs, particularly those that have recently been
recognised or suspected to be neurotoxic. We consider only
those forms of neuropathy resulting from the therapeutic use of
such drugs, and do not discuss the complications of drug
addiction.3
Awareness of the possibility of drug-induced peripheral nerve
damage is important because of the ever-increasing number of
therapeutic agents being introduced into clinical practice, and
prompt recognition of this complication is imperative if severe
neurological deficits are to be avoided. The incidence of drug-
induced peripheral neuropathy is difficult to establish, since the
association with drug treatment is not always recognised, mild
forms are easily overlooked, and subclinical disorders are
probably more frequent than is generally appreciated.4 5
Pathogenesis
Experimental studies have clarified the pathogenesis of certain
drug-induced neuropathies,7 but the basic mechanisms are generally
still poorly understood. Because these disorders are potentially
reversible the opportunities for histological and other studies of
peripheral nerve in man are limited. Nevertheless, with some
exceptions, such as perhexiline neuropathy, in which segmental
demyelination is prominent,8 axonal degeneration is the major
pathological process in most drug-induced neuropathies.
The mechanism of action of some drugs is relatively well under-
stood. Vincristine and colchicine have a specific effect on neuro-
tubules.9 10 Isoniazid interferes with pyridoxine metabolism,11
thalidomide inhibits riboflavine,'2 prolonged administration of
chloramphenicol may lead to vitamin Bl2 deficiency,13 and the
nitrofurans interfere with pyruvate oxidation by competing with
thiamine pyrophosphate.'4 Perhexiline may interfere with lipid
metabolism.15 Other drugs may cause ischaemic nerve damage by
inducing arteritis'; or severe vasospasm, as in chronic ergotism."'
Several factors may predispose to the neurotoxic effects of drugs.
The best-known genetic predisposition is the striking susceptibility
of the Japanese to develop subacute myelo-opticoneuropathy as a
complication of clioquinol treatment.' Variations in drug pharmaco-
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kinetics are also important. Slow acetylators of isoniazid are more
likely to develop peripheral neuropathy,l' as are patients with impaired
renal function, who may develop toxic blood concentrations of drugs
such as nitrofurantoin.'9 Strenuous exercise was thought to predispose
to the development of neuropathy in patients treated with the older
sulphonamides.20 The underlying disease may itself modify the
susceptibility to neuropathy-for example, patients with lymphoma
develop vincristine neuropathy more often than those with other
malignancies.21 Others who may be predisposed include patients with
cancer, diabetes, alcoholism, or vitamin deficiency, conditions in which
the peripheral nerves may already be affected.
Clinical presentations
Most of the drugs we considered cause either a purely sensory
neuropathy or a mixed sensorimotor neuropathy. Sensory mani-
festations usually precede motor disorders, and neurological deficits
usually develop first and are most severe distally in the legs.
Paraesthesiae alone are difficult to evaluate,22 but suggest that sensory
nerve function may be disturbed. Some drugs, such as dapsone,2'
cause an almost exclusively motor neuropathy. Symptoms of
autonomic dysfunction may be prominent, particularly in patients
with vincristine neuropathy.24 Localised damage to peripheral nerves
or a nerve plexus may result from intramuscular injections, intra-
arterial infusions of cytotoxic agents,25 26 or haemorrhage in patients
in whom anticoagulant treatment is poorly controlled.27 Brachial
plexus neuropathy may occasionally develop after intramuscular
injections of penicillin, presumably on an "allergic" basis.28 Certain
cranial nerves may also be affected, either selectively or as part of a
more generalised neuropathy, the optic,29 trigeminal,2 and eighth
cranial30 nerves being most often affected.
Specific drugs
The drugs that have been implicated and the clinical syndromes
they produce are listed in the table.
ANTIMICROBIAL AGENTS
Some of the antituberculosis agents in use may cause peripheral or
optic neuropathy. Isoniazid produces a mixed sensorimotor peripheral
neuropathy that may be prevented by giving vitamin B,, supplements."
The condition has been reviewed in detail by Le Quesne.' Ethambutol
is less neurotoxic but may cause optic neuropathy," a mixed sensori-
motor neuropathy, or a predominantly sensory neuropathy."
Ethionamide, which is structurally related to isoniazid, may rarely
cause peripheral neuropathy,'4 as may streptomycin after prolonged
administration,35 although this is less frequent than the ototoxic
effects of the drug.
Sensorimotor neuropathy ofvariable severity in patients treated with
nitrofurantoin is well recognised.'6 Symptoms may develop during or
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after a course of treatment, particularly in patients with renal
insufficiency. Electrophysiological studies have shown a high
incidence of subclinical neuropathy, even in non-uraemic patients,17
and in healthy volunteers taking therapeutic doses of the drug.4
Histological studies have shown axonal degeneration in peripheral
nerves and associated spinal cord damage in a postmortem study.'
Long-term experimental studies have shown evidence of a "dying-
back" neuropathy.
There are several reports of sensory neuropathy developing in
patients treated with conventional doses of metronidazole for 6-24
weeks.38-40 Electrophysiological studies have shown that both sensory
and motor nerve fibres may be affected.40 A sural-nerve biopsy
specimen from one patient showed axonal degeneration affecting both
small- and large-diameter fibres.40 The neuropathy is reversible after
withdrawal of the drug but recovery may be protracted. The incidence
of this complication is not known, and further clinical and electro-
physiological studies of patients receiving short- and long-term
treatment are required.
ANTINEOPLASTIC AGENTS
The vinca alkaloids, which have been used in treating various forms
of malignancy, are particularly neurotoxic. Most patients receiving
long-term vincristine treatment develop a peripheral neuropathy that
may be associated with a painful proximal myopathy.4' The clinical
features of vincristine neuropathy are well documented.4' 42 Both
sensory and motor nerves may be severely affected, and the tendon
reflexes are lost at an early stage. Postural hypotension and constipation
due to autonomic disorders may be early symptoms.24 Electro-
physiological studies have shown evidence of severe axonal damage
affecting motor and sensory fibres,4' the reflex loss probably being
due to damage to afferent fibres from the muscle spindles.43 Histo-
logical studies have shown severe axonal degeneration with only minor
segmental demyelination.4' Several other cytotoxic drugs may cause
peripheral nerve damage but are less neurotoxic than vincristine
(table).
CARDIOVASCULAR DRUGS
Peripheral neuropathy has been recognised only relatively recently
in patients treated with the coronary vasodilator perhexiline, but is
now well documented.8 44-46 Symptomatic neuropathy occurs in about
0 1 00 of treated patients, but subclinical disorders have been found in
as many as two-thirds of patients studied electrophysiologically.5
Sensory symptoms, including muscle pain and tenderness, are usually
prominent, appearing as early as three weeks after treatment begins,
and may be followed by severe weakness of distal and even of proximal
muscle groups. In most cases symptoms have occurred only after
several months of treatment with daily doses of 200-300 mg of the
drug. Papilloedema, dysgeusia, deafness, cerebellar signs, autonomic
disorders, and raised concentrations of protein in cerebrospinal fluid
have been reported.46 47 Histological studies of peripheral-nerve
biopsy specimens have shown prominent segmental demyelination
Clinical syndromes of drug-induced neuropathy and drugs implicated*
Clinical Antimicrobial Antineoplastic Cardiovascular Hypnotics and Antirheumatic Other drugs
presentation drugs drugs drugs psychotropics drugs
{ ethionamide procarbazine'9 calcium carbimide
Sensory chloramphenicol4 nitrofurazonel sulfoxone
neuropathy thiamphenicol95 ergotamine
diamines'6 propylthiouracil105
Paraesthesiae r colistin2" cytarabine9' propranolol22 phenelzine sulthiame22
only 1. streptomycin chlorpropamide2'ony nalidixic acid22 methysergide22
isoniazid vincristine perhexiline thalidomidel gold phenytoin
ethambutol podophyllum" hydrallazine methaqualone indomethacin disulfiram
Sensorimotor streptomycin chlorambucill ' amiodarone glutethimide colchicine'19' carbutamide2
neuropathy nitrofurantoin disopyramide amitriptyline chloroquine tolbutamide'23
clioquinoll clofibrate phenylbutazone chlorpropamide0'4
t metronidazole methimazole'06
Predominantly sulphonamides20 9T imipramine dapsone
motor V amphotericin
Localised f amphotericin2 mustine2 anticoagulants
neuropathies 1 penicillin ethoglucid2G
*References are given only for drugs not discussed in the text.
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with associated axonal degeneration, and membranous and para-
crystalline inclusions in Schwann cells and endothelial cells.8 48
Biochemical studies have shown an increased ganglioside content in
peripheral nerve.15 Complete recovery usually occurs within several
months of stopping treatment.
A predominantly sensory neuropathy may occur in patients treated
with hydrallazine.49 " Mild or subclinical neuropathy may occur in as
many as 15") of patients taking the drug.51 This seems to be unrelated
to the systemic lupus erythematosus-like syndrome induced by the
drug, and may be due to a disturbance of pyridoxine metabolism,
since hydrallazine is structurally related to isoniazid.52 Peripheral
neuropathy may occasionally develop in patients receiving
amiodarone5; or disopyramide.54 The evidence suggests that
amiodarone causes a demyelinating neuropathy. Rarely peripheral
nerves may be affected in patients with the typical painful myopathy
caused by clofibrate. 5 5'i
HYPNOTIC AND PSYCHOTROPIC DRUGS
Several reports have raised suspicion that methaqualone may be
neurotoxic. Some patients have transient acroparaesthesiae or
numbness shortly after taking the drug before the onset of sleep.57
At least 11 cases of a sensorimotor neuropathy have been reported in
patients taking 200-600 mg of methaqualone nightly for a few days
to two years, either alone or with diphenhydramine, diazepam,
meprobamate, or promazine.58-60 Symptoms improved in most
patients after methaqualone was withdrawn, improvement being
rapid and complete in those whose symptoms were of recent onset.
In a German study of 232 patients taking the drug, 44 of whom had
undergone electromyographic studies, only a single case of peripheral
neuropathy was found.6' Few cases of neuropathy have been reported
in Great Britain, and further clinical and electromyographic studies of
regular consumers of the drug are required to determine the incidence
of this complication.
A predominantly motor neuropathy may occasionally develop in
patients treated with imipramine62 63 and amitriptyline,64 but such
cases have not been studied fully. Reports of "neuritis" developing
in patients receiving chlorprothixene and of acroparaesthesiae in
those receiving phenelzine are difficult to evaluate.2 22 Sensory
neuropathy has been described in patients addicted to glutethimide
but is not a complication of conventional use of the drug.5 66
ANTIRHEUMATIC DRUGS
Peripheral neuropathy occurs in 0 5-1 ',, of patients with rheumatoid
arthritis who have gold treatment.67"'i Motor disorders are prominent
and sensory symptoms may be inconspicuous. An abrupt onset and
rapid progression in some cases, and associated facial diplegia and
raised protein concentration in cerebrospinal fluid may mimic acute
postinfective polyneuropathy. Few cases have been studied electro-
physiologically or pathologically but axonal degeneration appears to
be the main process.'; Indomethacin has also been implicated in
causing a neuropathy. A report on four patients with a sensorimotor
neuropathy and two with sensory symptoms only suggested that the
drug was responsible.-" Electromyographic studies showed con-
siderable slowing of motor conduction velocities in one case. Further
studies are needed to determine the incidence of this complication.
Chloroquine may cause a mild sensorimotor neuropathy as well as a
severe vacuolar myopathy.71-7' Histological studies have shown both
axonal degeneration and damage to Schwann cells. 74 Peripheral
neuropathy has been reported in patients treated with penicillamine,75
but less often than the myasthenic syndrome that develops in some
patients treated with the drug. The mechanism of the neuropathy may
be related to that caused by isoniazid, since penicillamine has an
antipyridoxine effect. Paraesthesiae and muscle weakness have been
reported in some patients treated with phenylbutazone but are
difficult to evaluate.7
ANTICONVULSANTS
Patients receiving long-term phenytoin treatment may develop a
predominantly sensory polyneuropathy that is usually mild and rarely
causes symptoms.78 79 The incidence of this complication is uncertain,
but signs of peripheral nerve disorders, such as depression of tendon
reflexes, are found increasingly often in patients receiving prolonged
treatment.80 Electrophysiological studies have shown that subclinical
lesions are common and that the neuropathy is of the "dying-back"
axonal degeneration type.80 The drug also has acute, reversible
effects, particularly on slow-conducting motor nerve fibres.8' 82
There is no convincing evidence to show that any of the other
commonly used anticonvulsants cause peripheral nerve damage.
OTHER DRUGS
Disulfiram and citrated calcium carbimide,83 which are used in
treating alcoholism, may both cause peripheral neuropathy. Disulfiram
causes a sensorimotor neuropathy with axonal degeneration and may
also cause optic-nerve damage.84-87 These effects may be due to its
neurotoxic metabolite carbon disulphide.' A number of the sulphones
may also cause neuropathy. Dapsone, which has been used in treating
leprosy and several dermatological conditions, may cause a subacute,
almost purely motor neuropathy, particularly after prolonged high-
dose treatment.'1 8892 Sulfoxone sodium, on the other hand, may
cause a purely sensory neuropathy.93
Conclusions
Drugs used in treating various conditions may cause peripheral
nerve damage. This may be clinically manifest, but in many
instances is asymptomatic. We suggest that a careful neurological
examination and studies of motor and sensory nerve conduction
should be performed in patients who complain of paraesthesiae,
pain, muscle cramps, weakness, or other abnormal sensations
during drug treatment. Investigation of such patients and of
patients without symptoms who are being treated with drugs
that are known or suspected to be neurotoxic will allow the
incidence of drug-induced peripheral nerve damage to be
determined more precisely.
We thank Professor Sir John Walton, who kindly reviewed the
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Is there now a method by which people on continuous corticosteroids-for
instance,for Addison's disease-can be vaccinated against smallpox. Also,
may they have injections against yellow fever ?
Apart from the recent Birmingham outbreak, no cases of smallpox
have occurred anywhere in the world for nearly one year. It would
therefore seem an unwarrantable risk to vaccinate any person taking
continuous corticosteroids who has not been in actual contact with a
smallpox case. In such circumstances vaccination could be carried
out under cover of vaccinial globulin, which is distributed by the
Public Health Laboratory Service and is administered by
intramuscular injection in a dose that is dependent on body weight.
For an average adult this is 0 5 g.
As yellow fever vaccine is also made up of live virus, theoretically
it would seem prudent to avoid this vaccination in patients taking
steroids.
Will there be any harmful effect in the recipient if the bloodfrom a donor
who takes diuretic or iron tablets is usedfor transfusion ?
This is unlikely since patients requiring either iron or diuretic
treatment should not at the same time be donating blood for trans-
fusion. Iron entering blood after oral treatment or even if given
parenterally is unlikely to produce symptoms in a recipient. Only
free iron is toxic. Iron absorbed by mouth would be bound to trans-
ferrin in plasma, and parenteral iron would remain as part of a
larger organic complex. Similarly, the dose of diuretic in, say, 200 ml
of plasma in a unit of blood will be too small to produce an effect in
most recipients. An extensive review of untoward effects of transfusion
does not record any reported examples of recipients affected by such
preparations.'
Mollison, P L, Blood Transfusion in Clinical Medicine, 5th edn, p 571. London,
Blackwell, 1972.
Is dried yeast of value in the treatment of multiple sclerosis ?
I have not only never used dried yeast to treat multiple sclerosis but
I have never seen any results from a controlled study. I would doubt
very much whether it had any useful part to play in treating the
disease. One could only presume by its contents that it might be a
form of immunotherapy such as giving Corynebacterium parvum.
Until we know more about the aetiology of the disease I do not think
I would recommend it.
